Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Allogene Allo News

Allogene Allo News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Allogene Allo. Real-time updates on events, politics, business and more.

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

December 9, 2023
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile...
United States San Diego South San Francisco Madeleine Goldstein Leslie Bryant Christine Cassiano
Source: marketscreener.com

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

November 3, 2023
Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic...
South San Francisco United States San Diego Madeleine Goldstein Zachary Roberts Christine Cassiano
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B cell Lymphoma at the American Society of Clinical Oncology Annual Meeting

June 5, 2023
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today presented long-term follow up... | June 5, 2023
United States Christine Cassiano Zachary Roberts Allogene Allo Research Development European Hematology Association
Source: marketscreener.com

Allogene Therapeutics, Inc.: Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 4, 2023
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused
United States Christine Cassiano Allogene Allo Madeleine Goldstein Zachary Roberts Drug Administration
Source: finanznachrichten.de

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2023
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... | June 3, 2023
United States Allogene Allo Madeleine Goldstein Zachary Roberts Christine Cassiano American Society Of Clinical Oncology
Source: marketscreener.com

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

May 11, 2023
Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Allogene Therapeutics,... | May 11, 2023
United States Christine Cassiano Allogene Allo Javier Munoz American Society Of Clinical Oncology Congress On
Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science